SNGX: Soligenix, Inc. Stock

by  •  • Comments Off on SNGX: Soligenix, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4.58
Enterprise Value ($M) -0.60
Book Value ($M) 2.52
Book Value / Share 0.24
Price / Book 1.82
NCAV ($M) 2.23
NCAV / Share 0.21
Price / NCAV 2.05

Profitability (mra)
Return on Invested Capital (ROIC) -1.02
Return on Assets (ROA) -0.55
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.55
Current Ratio 1.55

Balance Sheet (mrq) ($M)
Current Assets 9.51
Assets 9.80
Liabilities 7.27
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.84
Operating Income -7.70
Net Income -6.14
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -8.60
Cash from Investing 0.00
Cash from Financing 3.66

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2023 ☐TRANSITION REPORT PURSUAN
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐TRANSITION REPORT PURSUANT T
2023-08-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐TRANSITION REPORT PURSUANT TO SEC
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-19 123,276 929,439 13.26
2024-04-18 598,129 1,114,766 53.66
2024-04-17 743,053 4,413,665 16.84
2024-04-16 1,644,077 9,091,655 18.08
2024-04-15 32,501,669 135,037,373 24.07

(click for more detail)

Similar Companies
SLS – SELLAS Life Sciences Group, Inc. SMFL – Smart for Life, Inc.
SNDL – SNDL Inc. SNOA – Sonoma Pharmaceuticals, Inc.
SNPX – Synaptogenix, Inc.


Financial data and stock pages provided by
Fintel.io